Abstract
Introduction When HIV/AIDS patients die from opportunistic infections that cause death to happen more quickly, competing dangers are present. The objective of the current study was to estimate the probability of HIV/AIDS patients dying from competing illnesses such as tuberculosis, diarrhea, other opportunistic infections, and unidentified infections.
Methods All regional states, including the administrative cities of Addis Abeba and Dire Dawa, a retrospective cohort research was carried out between November 2019 to March 2020. There were 39590 HIV-positive individuals considered. We used competing risk models with a time-to-death horizon of 1212 for the total number of HIV-positive people. A competing event was thought to be death from various causes.
Results Out of the total 1212 deaths, 542(44.7%) died competing with other opportunistic infection (TE-Esophageal Candidiasis, TO-oral, CT-CNS Toxoplasmosis, CM-Crypotococcal Meningitis…), 421 (34.7%) died due to tuberculosis and the remaining death were unknown/Not specified infection 222(18.3%) and diarrhea 27(2.2%). Rates of mortality caused by tuberculosis, competing with other opportunistic infection, diarrhea and unknown/Not specified were 3.5, 4.5, 0.2 and 1.8 per 1000 person-months, respectively. Responding to combined Antiretroviral Treatment (cART) 6 months after initiation, receiving Pneumocystis Pneumonia (PCP) prophylaxis, and higher CD4 count at diagnosis reduced the hazard of tuberculosis, other opportunistic infection and unknown and diarrhea causes of death. However, older age, late HIV.AIDS diagnosis, and the last HIV/AIDS WHO clinical stages increased the hazard of tuberculosis and other opportunistic disease mortality. Additionally, male gender, older age and last HIV clinical stages increased the mortality HIV/AIDS patients.
Conclusion The findings of this study demonstrated that TB, an opportunistic infection, was the primary cause of death in HIV/AIDS patients, despite the presence of several competing risks, such as diarrhea, other infections, and an undetermined or unclear cause. It’s important to use effective techniques to quickly detect those who have HIV or AIDS and provide them with care and treatment to increase their chances of surviving.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ALERT/Armauer Hansen’s Research Institute’s (AHRI’s) IRBs [P048/18].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Availability of data and materials
The data sets analyzed in this study available from the corresponding author on reasonable request. The R code used to analyze the data provided as a supplement of the article.
Abbreviations
- ART
- Antiretroviral therapy
- HAART
- Highly active antiretroviral therapy
- AHRI
- Armauer Hansen Research Institute
- AIDS
- Acquired Immunodeficiency Syndrome
- CD4
- Cluster of Differentiation 4 or Classification Determinant
- FHAPCO
- Federal HIV/AIDS Prevention & Control Office
- HIV
- Human Immunodeficiency Virus
- NAPES
- National ART Program Effectiveness Study
- IRB
- Institutional Review Board
